- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05167747
Food Supplementation With Diuripres for Blood Pressure Modulation in Subjects With High-Normal Blood Pressure (CONDOR)
Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Effect of a Combined Nutraceutical and Placebo on Blood Pressure Level, Vascular Health, and Metabolic Parameters in Subjects Affected by Normal-High Blood Pressure
Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching the 31% of deaths in 2012. CVDs represent also the major cause of disability in developed countries and has been estimated that their growing burden could lead to a global increase in loss of disability-adjusted life years (DALY), from a loss of 85 million DALYs of 1990 to a loss of ~ 150 million DALYs in 2020, becoming a major cause of no psychic responsible for lost productivity.
Several risk factors contribute to the aetiology and development of CVD. These factors have been traditionally stratified into modifiable risk factors through the lifestyle changes or by taking a pharmacologic treatment (e.g. hypertension, smoking, diabetes mellitus, hypercholesterolemia) and not modifiable risk factors (age, male sex and family history). Essential hypertension is the most common modifiable risk factor in the general population, with a prevalence in Western Countries -including Italy- ranging between about 25-45%.
Given the large prevalence of the disease of the general population, hypertension is responsible for the vast majority of CVD in individuals with different CV risk profiles, despite the availability of effective and well tolerated antihypertensive therapies. In this regard, several reports have shown that hypertensive patients often present additional CV and metabolic risk factors, mostly hypercholesterolemia, hypertriglyceridemia, metabolic syndrome and diabetes, which further contribute to increase the individual risk of developing hypertension-related complications, including stroke, end-stage renal disease, congestive heart failure, and CVD death. The concomitant presence of hypertension and dyslipidaemia is also responsible for the objective difficulty in achieving the recommended therapeutic targets for BP and cholesterol levels in a setting of clinical practice.
Several pharmacological and non-pharmacological interventions have been proposed for ameliorating the relatively low rates of control of hypertension. Among these, an extensive use of nutrients and food supplements has been shown to provide favourable effects in the management and control of high-normal blood pressure (BP) (or pre-hypertension), that increases the risk of developing hypertension, cardiovascular diseases, and renal failure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Among food supplements largely used in this field, Orthosiphon stamineus Benth leaf extract has been recognized for its well-known diuretic properties; extract of hawthorn (Crataegus curvisepala Lind.) has been shown to exert a renal-protective effect in high salt-induced hypertension and extract of hibiscus (Hibiscus sabdariffa L.) is well known for its antihypertensive and vasodilator effect in human. Moreover, supplementation with magnesium has been recently found to play a critical role in BP regulation, through directly stimulating prostacyclin and nitric oxide formation, modulating endothelium-dependent and endothelium-independent vasodilation, reducing vascular tone and reactivity, and preventing vascular injury via its antioxidant and anti-inflammatory functions.
The objective of this study is to evaluate the effect of dietary supplementation of a combined food supplement (NUT) containing magnesium, standardized extract of orthosiphon (Orthosiphon stamineus Benth), standardized extract of hawthorn (Crataegus curvisepala Lind.) and standardized extract of hibiscus (Hibiscus sabdariffa L.) compared to placebo, on blood pressure and other markers of vascular aging in subjects with high-normal blood pressure.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Arrigo F. Cicero, MD
- Phone Number: +39516362224
- Email: arrigo.cicero@unibo.it
Study Locations
-
-
-
Bologna, Italy
- S. Orsola-Malpighi University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects agree to participate in the study and having dated and signed the informed consent form;
- Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements;
- Subjects with high-normal blood pressure (SBP= 130-139 mmHg and/or DBP= 85-89 mmHg);
- Subjects who, according to the SCORE charts, have a low or moderate cardiovascular risk (defined as a total cardiovascular risk < 5%) and for whom, according to 2018 ESC/ESH guidelines, the intervention strategy does not require a pharmacological intervention.
Exclusion Criteria:
- Subjects already affected by cardiovascular diseases (secondary prevention) or with an estimated 10 years cardiovascular disease risk> 5%;
- Obesity (Body mass index>30 kg/m2);
- Type 1 or type 2 diabetes;
- Assumption of anti-hypertensive drugs or food supplements, or drugs potentially affecting blood pressure;
- Lipid-lowering treatment not stabilized since at least 2 months;
- Anticoagulants therapy;
- Known current thyroid, gastrointestinal or hepatobiliary diseases;
- Any medical or surgical condition that would limit the patient adhesion to the study protocol;
- Abuse of alcohol or drugs (current or previous);
- History of malignant neoplasia in the 5 years prior to enrolment in the study;
- History or clinical evidence of inflammatory disease such as severe arthritis, systemic lupus erythematosus or chronic inflammatory diseases or current therapy with immunosuppressive agents or long-term glucocorticoids;
- History or clinical evidence of any significant concomitant disease that could compromise the safety of the subject or the possibility of completing the study;
- Known previous intolerance to one component of the tested nutraceuticals;
- Women in fertile age not using consolidated contraceptive methods;
- Pregnancy and Breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo comparator
Placebo
|
Oral administration: 2 tablets/day at evening meal
|
Active Comparator: Active Comparator
Dietary supplement
|
Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.). Oral administration: 2 tablets/day at evening meal |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic blood pressure absolute reduction from baseline and between groups
Time Frame: 8 weeks
|
Absolute reduction of systolic blood pressure after 8 weeks of treatment
|
8 weeks
|
Diastolic blood pressure absolute reduction from baseline and between groups
Time Frame: 8 weeks
|
Absolute reduction of diastolic blood pressure after 8 weeks of treatment
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic blood pressure absolute reduction from baseline and between groups
Time Frame: 4 weeks
|
Absolute reduction of systolic blood pressure after 4 weeks of treatment
|
4 weeks
|
Diastolic blood pressure absolute reduction from baseline and between groups
Time Frame: 4 weeks
|
Absolute reduction of diastolic blood pressure after 4 weeks of treatment
|
4 weeks
|
Percent reduction from baseline and between groups in vascular reactivity
Time Frame: 4 weeks
|
Percent reduction of flow-mediated dilation (FMD) after 4 weeks of treatment
|
4 weeks
|
Percent reduction from baseline and between groups in vascular reactivity
Time Frame: 8 weeks
|
Percent reduction of flow-mediated dilation (FMD) after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in body weight
Time Frame: 4 weeks
|
Absolute change of body weight after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in body weight
Time Frame: 8 weeks
|
Absolute change of body weight after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in body mass index
Time Frame: 4 weeks
|
Absolute change of body mass index after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in body mass index
Time Frame: 8 weeks
|
Absolute change of body mass index after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in waist circumference
Time Frame: 4 weeks
|
Absolute change of waist circumference after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in waist circumference
Time Frame: 8 weeks
|
Absolute change of waist circumference after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in hip circumference
Time Frame: 4 weeks
|
Absolute change of hip circumference after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in hip circumference
Time Frame: 8 weeks
|
Absolute change of hip circumference after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in waist/hip circumference ratio
Time Frame: 4 weeks
|
Absolute change waist/hip circumference ratio after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in waist/hip circumference ratio
Time Frame: 8 weeks
|
Absolute change waist/hip circumference ratio after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in the index of central obesity
Time Frame: 4 weeks
|
Absolute change of the index of central obesity after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in the index of central obesity
Time Frame: 8 weeks
|
Absolute change of the index of central obesity after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in the visceral adiposity index
Time Frame: 4 weeks
|
Absolute change of the visceral adiposity index after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in the visceral adiposity index
Time Frame: 8 weeks
|
Absolute change of the visceral adiposity index after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in fat and lean mass
Time Frame: 4 weeks
|
Absolute change of fat and lean mass after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in fat and lean mass
Time Frame: 8 weeks
|
Absolute change of fat and lean mass after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in renal function
Time Frame: 4 weeks
|
Absolute change of creatinine and the estimated glomerular filtration rate (eGFR) after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in renal function
Time Frame: 8 weeks
|
Absolute change of creatinine and the estimated glomerular filtration rate (eGFR) after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in serum lipids
Time Frame: 4 weeks
|
Absolute change of serum concentrations of total cholesterol, triglycerides - TG, high-density lipoprotein cholesterol - HDL-C, non-high-density lipoprotein cholesterol - non HDL-C, low-density lipoprotein cholesterol - LDL-C after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in lipids ratios
Time Frame: 4 weeks
|
Absolute change of lipids ratios after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in serum lipids
Time Frame: 8 weeks
|
Absolute change of serum concentrations of total cholesterol, triglycerides - TG, high-density lipoprotein cholesterol - HDL-C, non-high-density lipoprotein cholesterol - non HDL-C, low-density lipoprotein cholesterol - LDL-C after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in serum lipids ratios
Time Frame: 8 weeks
|
Absolute change of lipids ratios after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in high sensitivity C reactive protein
Time Frame: 4 weeks
|
Absolute change of high sensitivity C reactive protein (hsCRP) after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in high sensitivity C reactive protein
Time Frame: 8 weeks
|
Absolute change of high sensitivity C reactive protein (hsCRP) after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in serum uric acid concentrations
Time Frame: 4 weeks
|
Absolute change of serum uric acid after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in serum uric acid concentrations
Time Frame: 8 weeks
|
Absolute change of serum uric acid after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in fasting plasma glucose concentrations
Time Frame: 4 weeks
|
Absolute change of fasting plasma glucose after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in fasting plasma glucose concentrations
Time Frame: 8 weeks
|
Absolute change of fasting plasma glucose after 8 weeks of treatment
|
8 weeks
|
Treatment acceptability
Time Frame: 4 weeks
|
Evaluation of patients' satisfaction assessed by a Visual Analogue Scale (VAS) scale (with two end points representing 0 -low acceptability- and 10 -high acceptability-) after 4 weeks of treatment
|
4 weeks
|
Treatment acceptability
Time Frame: 8 weeks
|
Evaluation of patients' satisfaction assessed by a Visual Analogue Scale (VAS) scale (with two end points representing 0 -low acceptability- and 10 -high acceptability-) after 8 weeks of treatment
|
8 weeks
|
Treatment tolerability
Time Frame: 4 weeks
|
Evaluation of treatment's tolerability assessed by patients with a Visual Analogue Scale (VAS) scale (with two end points representing 0 -no pain- and 10 -pain as bad as it could possibly be-) after 4 weeks of treatment
|
4 weeks
|
Treatment tolerability
Time Frame: 8 weeks
|
Evaluation of treatment's tolerability assessed by patients with a Visual Analogue Scale (VAS) scale (with two end points representing 0 -no pain- and 10 -pain as bad as it could possibly be-) after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in liver transaminases and gamma glutamil transferase
Time Frame: 4 weeks
|
Absolute reduction of alanine aminotransferase, aspartate aminotransferase and gamma glutamil transferase after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in liver transaminases and gamma glutamil transferase
Time Frame: 8 weeks
|
Absolute reduction of alanine aminotransferase, aspartate aminotransferase and gamma glutamil transferase after 8 weeks of treatment
|
8 weeks
|
Absolute change from baseline and between groups in augumentation pressure
Time Frame: 4 weeks
|
Absolute change of augumentation pressure after 4 weeks of treatment assessed by Vicorder software
|
4 weeks
|
Absolute change from baseline and between groups in augumentation index
Time Frame: 4 weeks
|
Absolute change of augumentation index after 4 weeks of treatment assessed by Vicorder software
|
4 weeks
|
Absolute change from baseline and between groups in augumentation pressure
Time Frame: 8 weeks
|
Absolute change of augumentation pressure after 8 weeks of treatment assessed by Vicorder software
|
8 weeks
|
Absolute change from baseline and between groups in augumentation index
Time Frame: 8 weeks
|
Absolute change of augumentation index after 8 weeks of treatment assessed by Vicorder software
|
8 weeks
|
Percent change from baseline and between groups in the estimated body water content
Time Frame: 4 weeks
|
Percent change of the body water content after 4 weeks of treatment, assessed by bioelectrical impedance analysis (BIA)
|
4 weeks
|
Percent change from baseline and between groups in the estimated body water content
Time Frame: 8 weeks
|
Percent change of the body water content after 8 weeks of treatment, assessed by bioelectrical impedance analysis (BIA)
|
8 weeks
|
Absolute change from baseline and between groups in estimated risk of cardiovascular disease
Time Frame: 4 weeks
|
Absolute change of the percent estimated risk of cardiovascular disease after 4 weeks of treatment
|
4 weeks
|
Absolute change from baseline and between groups in estimated risk of cardiovascular disease
Time Frame: 8 weeks
|
Absolute change of the percent estimated risk of cardiovascular disease after 8 weeks of treatment
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Arrigo F. Cicero, MD, S. Orsola-Malpighi University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Pre-HPT_RCT_2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-Normal Blood Pressure
-
GE HealthcareTerminatedBlood Pressure (Low, Normal, High)United States
-
China National Center for Cardiovascular DiseasesRecruitingHypertension | High-normal Blood PressureChina
-
Maharishi International UniversityAmerican University; Abramson Family FoundationCompletedPsychological Stress | High-normal Blood PressureUnited States
-
University of VigoBayer; Hospital Clinico Universitario de SantiagoTerminatedHigh-Normal Blood Pressure | Mild Essential HypertensionSpain
-
Umeå UniversityCompletedIdiopathic Normal Pressure Hydrocephalus
-
Uppsala University HospitalUppsala University; Swedish Society for Medical ResearchRecruitingIdiopathic Normal Pressure Hydrocephalus (INPH)Sweden
-
Johns Hopkins UniversityUniversity of Utah; Integra LifeSciences CorporationCompletedIdiopathic Normal Pressure Hydrocephalus (INPH)United States, Canada, Sweden
-
Dokuz Eylul UniversityRecruitingNPH (Normal Pressure Hydrocephalus)Turkey
-
University of ZurichRecruitingIdiopathic Normal Pressure HydrocephalusSwitzerland
-
Second Affiliated Hospital, School of Medicine,...Westlake UniversityUnknownIdiopathic Normal Pressure HydrocephalusChina
Clinical Trials on Dietary Supplement
-
University of Novi Sad, Faculty of Sport and Physical...Completed
-
Fonterra Research CentreCompleted
-
Universidade Federal do AmazonasCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Hospital Universitario... and other collaboratorsCompletedOverweight | HypercholesterolemiaBrazil
-
Larissa University HospitalRecruitingDumping Syndrome | Gastric SurgeryGreece
-
Texas Tech UniversityEHP LabsCompletedBody Weight Changes | Body Composition Changes | Anthropometric Changes | Metabolism Changes | Hemodynamic ChangesUnited States
-
University of PrimorskaCommunity Healthcare Center dr. Adolf Drolc Maribor (HCM)Not yet recruitingOsteoarthritis, KneeSlovenia
-
Henrik GudbergsenUnknownObesity | OsteoarthrtisDenmark
-
L'OrealNestléCompleted
-
Assiut UniversityUnknownCritical Illness